dacomitinib

Tagrisso

Pharma

NICE shuts down AZ's Tagrisso—and backs a Pfizer rival instead

England’s cost watchdogs won’t get behind AZ blockbuster Tagrisso. But in a change of events, they’re instead backing a Pfizer challenger.

Carly Helfand Jul 8, 2019 10:30am

Pfizer

Pfizer's once-failed Vizimpro rebounds with FDA lung cancer nod

Sep 28, 2018 10:35am

Pfizer HQ

Pfizer's dacomitinib finally wins in ph3 against AZ's Iressa

Jun 5, 2017 7:30am